Evidence map›Paper›PMID 32574262›Full record

Trial reportFrontiers in immunology2020

Interferon-α2b Treatment for COVID-19.

Qiong Zhou, Virginia Chen, Casey P Shannon, Xiao-Shan Wei, Xuan Xiang, Xu Wang, Zi-Hao Wang, Scott J Tebbutt, Tobias R Kollmann, Eleanor N Fish

Erratum issued 2 registry-linked trialsOpen access · goldAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 2 registered trials, which are not on this map. Cited by 261 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
261citing papers in PubMed, 7 pooled it
9.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04672291 phase1completednot on this mapstarted 2021, after this paper: background citation

A Phase I-Ib, Double-blinded, Randomized Repeated Dose Single Center, Safety and Immunogenicity Study of Nasal Poly-ICLC (Hiltonol®) in Healthy COVID-19 Vaccinated Adults

TypeinterventionalSponsorOncovir, Inc.Ran2021 to 2023Enrolled43ConditionsCOVID - 19ArmsPoly-ICLC (Hiltonol®) or Placebo
NCT05381363 phase1 / phase2terminatednot on this mapstarted 2022, after this paper: background citation

Inhaled Interferon α2b Treatment in Mild-to-moderate COVID-19 Infected Children

TypeinterventionalSponsorChildren's Hospital of Fudan UniversityRan2022 to 2023Enrolled24ConditionsCOVID-19, ChildrenArmsInhaled Interferon α2b, Standard of Care
3 · Its place in the literature

Who cites it

261 citing papers in PubMed, 7 syntheses or guidelines pooled it, 386 citations in OpenAlex.

  1. Innate immunity to SARS-CoV-2 infection: a review.Epidemiology and infection · 2022
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Immunomodulation as Treatment for Severe Coronavirus Disease 2019: A Systematic Review of Current Modalities and Future Directions.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021
    Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Efficacy and safety of pegylated interferon-α2b in moderate COVID-19: a phase 3, randomized, comparator-controlled, open-label study.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2021
    Trial
  13. Trial
  14. Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2021
    Trial
  15. Trial
  16. Trial
  17. Article
  18. Article
  19. Article
  20. Article

201 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 3 countries.

Qiong ZhouDepartment of Respiratory and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Virginia ChenPrevention of Organ Failure (PROOF) Centre of Excellence and Centre for Heart Lung Innovation, St Paul's Hospital, University of British Columbia, Vancouver, BC, Canada.
Casey P ShannonPrevention of Organ Failure (PROOF) Centre of Excellence and Centre for Heart Lung Innovation, St Paul's Hospital, University of British Columbia, Vancouver, BC, Canada.
Xiao-Shan WeiDepartment of Respiratory and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Xuan XiangDepartment of Respiratory and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Xu WangDepartment of Respiratory and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Zi-Hao WangDepartment of Respiratory and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Scott J TebbuttPrevention of Organ Failure (PROOF) Centre of Excellence and Centre for Heart Lung Innovation, St Paul's Hospital, University of British Columbia, Vancouver, BC, Canada.
Tobias R KollmannSystems Vaccinology, Center for Precision Health, Telethon Kids Institute, Nedlands, WA, Australia.
Eleanor N FishToronto General Hospital Research Institute, University Health Network and Department of Immunology, University of Toronto, Toronto, ON, Canada.
Union Hospital · CNHuazhong University of Science and Technology · CNPrevention of Organ Failure · CASt. Paul's Hospital · CAThe Kids Research Institute Australia · AUUniversity Health Network · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The global pandemic of COVID-19 cases caused by infection with SARS-CoV-2 is ongoing, with no approved antiviral intervention. We describe here the effects of treatment with interferon (IFN)-α2b in a cohort of confirmed COVID-19 cases in Wuhan, China. In this uncontrolled, exploratory study, 77 adults hospitalized with confirmed COVID-19 were treated with either nebulized IFN-α2b (5 mU b.i.d.), arbidol (200 mg t.i.d.) or a combination of IFN-α2b plus arbidol. Serial SARS-CoV-2 testing along with hematological measurements, including cell counts, blood biochemistry and serum cytokine levels, and temperature and blood oxygen saturation levels, were recorded for each patient during their hospital stay. Treatment with IFN-α2b with or without arbidol significantly reduced the duration of detectable virus in the upper respiratory tract and in parallel reduced duration of elevated blood levels for the inflammatory markers IL-6 and CRP. These findings suggest that IFN-α2b should be further investigated as a therapy in COVID-19 cases.

Indexed as

AdultAgedAged, 80 and overAge FactorsAntiviral AgentsBiomarkersChinaCohort StudiesComorbidityCoronavirus InfectionsCOVID-19CytokinesDrug Therapy, CombinationFemaleHumansIndolesAntiviral AgentsBiomarkersCytokinesIndolesInterferon-alphaInterferon alpha-2Interferon-alpha2bSulfidesumifenovirARDSCOVID-19IL-6inflammationinterferonviral shedding

Identifiers

PMID32574262
PMCPMC7242746
OpenAlexW3025395896

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.